Vaxcyte (PCVX) Q4 FY25 earnings call: guidance and Q&A

How is OPUS-1 powered for noninferiority against PCV20 and PCV21 independently, and what remains to be discussed with FDA for the manufacturing consistency study?

OPUS-1 is powered with high confidence against PCV20 based on prior data, and against PCV21 by looking at their comparisons to PCV20. For the 10 common serotypes, noninferiority to either comparator is sufficient. For incremental serotypes, VAX-31 has a strong profile. Management emphasized that perfection is not required for approval, as totality of data and broader coverage are key. Manufacturing consistency discussions with FDA are constructive and tracking well for BLA timing.

“A successful result, as we pointed out in the call today, is not perfection, right? No pneumococcal conjugate vaccine has ever had a perfect slate of comparisons to the standard of care vaccines. These vaccines are approved based on the totality of what they offer over and above the standard of care vaccines.”

asked by Jiale Song · answered by Grant Pickering

What needs to be shown against PCV21 for a catch-up recommendation, and what drives confidence in the new infant dosing regimen for serotypes needing an immunogenicity boost?

For catch-up, VAX-31 needs to demonstrate improved responses to previously vaccinated serotypes and robust immunogenicity for incremental serotypes. The goal is to expand coverage and potentially boost responses. For infants, the new higher doses in VAX-31 Phase II are designed to enhance immune responses for serotypes that showed room for improvement in VAX-24, aiming to recover as many as possible, while acknowledging that perfection is not required for a 31-valent vaccine offering significantly broader coverage.

“what we're looking to show is continued strong, robust responses on the serotypes for which there is the most strategic importance. Those are the strains that are circulating. And then for those serotypes where we did show room for improvement that aren't circulating, we'll look to recover as many of those as possible.”

asked by Jonathan Miller · answered by Grant Pickering

What are the development plans for VAX-A1, is there a standardized immunogenicity standard, and would an efficacy trial be expected for Phase III?

The plan is to start Phase I in adults, assessing safety and immunogenicity (IgA and IgG in serum and saliva). There is no correlative protection, so efficacy cannot be predicted from immunogenicity. However, due to the ubiquity of strep throat in school-entry kids, a small proof-of-concept study (hundreds to low thousands) could provide an early read on efficacy before a full Phase III.

“what's unique about Group A Strep is that strep throat is so ubiquitous in school entry kids that we can do a very small study, and you're talking hundreds, maybe just barely in the thousands, and you can really get an early read on proof-of-concept even before going into a Phase III.”

asked by Erik Lavington · answered by James Wassil

Does VAX-A1 resumption reflect updated financial position or increased confidence? How are post-marketing efficacy studies for VAX-31 being tackled compared to Merck/Pfizer?

VAX-A1 resumption is primarily due to the strengthened financial position from the recent equity offering, which extended the cash runway to end of 2028, enabling advancement of pipeline programs while preserving PCV milestones. Post-marketing efficacy studies for VAX-31 will be consistent with agreements made for currently marketed PCVs (Merck/Pfizer), involving a test-negative design surveillance approach to monitor pneumonia cases.

“that decision was made principally for financial reasons to extend our runway to ensure we could deliver on the key milestones for our PCV franchise... one of the benefits of the financing was to enable us to, again, resume advancement of the pipeline programs.”

asked by Boran Wang · answered by Andrew Guggenhime

How should commentary on regulatory flexibility for individual serotypes extend to serotype 3, given its importance, and what are the commercial implications of demonstrating noninferiority there?

FDA has stated flexibility on missing a few serotypes without designation. Serotype 3 is an outlier; despite inclusion in vaccines, it remains top circulating due to insufficient antibody responses from any vaccine. While some vaccines showed statistically higher responses for serotype 3, it hasn't been clinically meaningful or a competitive differentiator. Vaxcyte's VAX-31 and VAX-24 data showed better serotype 3 responses than Prevnar 20. The company does not expect serotype 3 to be a competitive differentiator.

“serotype 3 is just the total outlier. And even though there have been some of the vaccines that have been able to show higher serotype immune responses relative to others, unfortunately, they're all still well below that protected threshold.”

asked by Carter Gould · answered by Grant Pickering

What is the bull case for OPUS-1 data beyond regulatory approval, and where does the VAX-XL program sit in development?

The bull case emphasizes that "coverage is king," as demonstrated by Capvaxive's market share gains. VAX-31 offers a significant coverage advantage (31 serotypes vs. 20/21). While superiority in immunogenicity has been rare, VAX-31 showed directionally higher responses in 18 of 20 common serotypes and statistically significantly higher in 7 of 20 in Phase II vs. Prevnar 20. Combining broad coverage with improved immune responses would be a strong bull case. VAX-XL is a third-generation, broader-spectrum vaccine (beyond 31 serotypes), currently a life cycle management strategy. It's not needed yet due to VAX-31's high coverage (95-98%), but is being prepared for potential future serotype replacement.

“I think it is a very different set of arguments when you're combining coverage and improved immune responses. And of course, this is in the context of the historical trade-off where you're training coverage for lower immune responses. So we've really flipped the script on being able to have the opportunity to demonstrate both.”

asked by Dina Ramadane · answered by Grant Pickering

Which of OPUS-2 or OPUS-3 is more commercially meaningful and why, and how could they impact ACIP recommendations beyond OPUS-1?

Both studies contribute to the BLA and safety database. OPUS-2 (concomitant flu vaccination) is helpful but not instrumental. OPUS-3 (previously vaccinated adults) is strategically more important due to the potential for a "catch-up recommendation." This could unlock a large bolus market of individuals who received lower valency vaccines, providing significant commercial potential by expanding coverage and boosting responses.

“I do think the OPUS-3 study is perhaps a more strategically important outcome... that could create a really large bolus market that we would work through over many years to give as many people the benefit of the breadth of coverage that VAX-31 could provide.”

asked by Tara Bancroft · answered by Grant Pickering